2160
V.V. Tumanov et al. / Tetrahedron 66 (2010) 2156–2161
3.3.5. DCHC complex of 5-methyl-5-[(4-chlorophenylthio)methyl]-3-
methylenehept-1-en-6-yne (10). Following the procedure described
for 6, the DCHC complex 1b (352 mg, 1.0 mmol) and diene 5c
(210 mg, 1.5 mmol) were converted into the adduct 10.
Compound 10: 462 mg, 82%, dark brownish oil. Rf 0.61 (SiO2,
ethyl acetate/hexane, 1:10). 1H NMR (250 MHz, CDCl3): 1.33 (s, 3H),
2.54 and 2.77 (both d, J¼13.5, 1H each), 3.09 (s, 2H), 5.13 (d, J¼11.0,
1H), 5.20 and 5.32 (both s,1H each), 5.35 (d, J¼19.0,1H), 6.34 (s,1H),
6.46 (dd, J1¼11.0, J2¼19.0,1H), 7.20 and 7.25 (both d, J¼8.8, 2H each).
Compound 100: 82% from 10, Rf 0.60 (SiO2, ethyl acetate/hexane,
1:10). Elemental analysis calcd (%) for C16H17ClS: C, 69.42; H, 6.19.
Found (%): C, 69.61; H, 6.43.
anti- and syn-, 1H in all), 3.01 (dd, syn-, J1¼13.1, J2¼10.0, 1H), 3.08
(m, anti-, 2H), 3.36 (dd, syn-, J1¼13.1, J2¼4.6, 1H), 3.52 and 3.65
(both m, syn- and anti-, 1H in all), 5.87 and 6.15 (both s, syn- and
anti-,1H in all), 7.27 and 7.31 (2d, syn- and anti-, J¼8.5, 4H in all). 13C
NMR (125 MHz, CDCl3): 20.3, 25.5, 38.5, 39.6, 41.0, 52.6, 129.3,
130.7, 131.2, 132.8, 133.6, 216.30.
Compound 130 (syn/anti): 91% from 13, Rf 0.27 (SiO2, ethyl
acetate/hexane,1:10). 1H NMR (500 MHz, CDCl3): 1.78 (m,1H in all),
1.92 (m, 1H in all), 2.09 (s, 1H in all), 2.11 (m, 3H in all), 2.31 (m, 1H
in all), 2.51 and 2.82 (m, syn- and anti-, 1H in all), 2.93 (dd, syn-,
J1¼11.4, J2¼8.0, 1H), 3.11 (m, 1H in all), 3.15 (dd, syn-, J1¼11.4, J2¼7.5,
1H), 3.27 (m, anti-, 2H), 7.24 and 7.31 (both d, anti-, J¼8.8, 2H each),
7.25 and 7.29 (both d, syn-, J¼8.5, 2H each). 13C NMR (125 MHz,
CDCl3): 20.4, 24.9, 31.3, 37.6, 38.5, 50.2, 72.0, 82.6, 129.3, 131.6,
132.9, 133.3, 209.8. Elemental analysis calcd (%) for C15H15ClOS: C,
64.62; H, 5.42. Found (%): C, 64.81; H, 5.59.
3.3.6. DCHC complex of 2,4-dimethyl-4-[(4-chlorophenylthio)-
methyl]-hex-1-en-5-yne (11). Following the procedure described
for 6, the DCHC complex 1b (352 mg, 1.0 mmol) and methallyl-
trimethylsilane (5d) (192 mg, 1.5 mmol) were converted into the
adduct 11.
Compound 11: 442 mg, 80%, dark brownish oil. Rf 0.57 (SiO2,
ethyl acetate/hexane, 1:10). 1H NMR (250 MHz, CDCl3): 1.41 (s, 3H),
2.26 and 2.61 (both d, J¼13.4,1H each), 3.12 (s, 2H), 4.91 (s,1H), 5.01
(s, 1H), 6.29 (s, 1H), 7.24 (s, 4H).
Compound 110: 82% from 11, Rf 0.55 (SiO2, ethyl acetate/hexane,
1:10). Elemental analysis calcd (%) for C15H17ClS: C, 68.03; H, 6.47.
Found (%): C, 68.30; H, 6.20.
3.3.9. DCHC complex of 2-[2-methyl-1-(4-chlorophenylthio)but-3-
yn-2-yl]cyclopentanone (14). Following the procedure described
for 6, the DCHC complex 1b (352 mg, 1.0 mmol) and trimethyl-
silyloxycyclopentene-1 (5f) (234 mg, 1.5 mmol) were converted
into the mixture of syn/anti isomers of 14 (551 mg, 95%, dark
brownish oil, Rf 0.29 (SiO2, ethyl acetate/hexane, 1:10), syn/
anti¼3.0:1, the ratio was determined by comparison of 1H NMR
signal intensity).
Compound 14 (syn/anti): 1H NMR (500 MHz, CDCl3): 1.38 and
1.42 (both s, syn- and anti-, 3H in all), 1.70 (m, 1H in all), 2.01 (m, 2H
in all), 2.17 (m, 2H in all), 2.34 (m, 1H in all), 2.58 (m, 1H in all), 3.19
and 3.52 (both d, anti-, J¼12.5, 1H each), 3.44 and 3.52 (both d, syn-,
J¼12.5, 1H each), 6.12 and 6.16 (both s, 1H in all), 7.22 and 7.31 (both
d, syn-, J¼8.6, 2H each), 7.23 (s, anti-, 4H).
3.3.7. 1,2-DCHC complex of 7-trimethylsilyl-3-[(4-chlorophenylthio)-
methyl]-3-methyl-5-methylenehepta-1,6-diyne (12). Following the
procedure described for 6, the DCHC complex 1a (338 mg,
1.0 mmol) and 4-trimethylsilyl-2-trimethylsilylmethyl-2-buten-3-
yne (5e) (315 mg, 1.5 mmol) were converted into the adduct 12.
Compound 12: 378 mg, 61%, dark brownish oil. Rf 0.56 (SiO2,
ethyl acetate/hexane, 1:10). 1H NMR (300 MHz, CDCl3): 0.10 (s, 9H),
2.31 (dd, J1¼7.2, J2¼13.8, 1H), 2.74 (dd, J1¼6.8, J2¼13.8, 1H), 3.09 (m,
2H), 3.32 (m, 1H), 5.32 (s, 1H), 5.51 (s, 1H), 6.23 (s, 1H), 7.25 and 7.30
(both d, J¼7.7, 2H each). 13C NMR (75 MHz, CDCl3): 0.3, 40.2, 40.6,
43.6, 75.5, 95.6, 98.6, 103.9, 124.6, 129.4, 130.8, 132.3, 133.6, 134.4,
199.7.
Compound 140 (syn/anti): 92% from 14, Rf 0.27 (SiO2, ethyl ace-
tate/hexane, 1:10). 1H NMR (250 MHz, CDCl3): 1.29 and 1.45 (both s,
anti- and syn-, 3H in all), 1.72 (m, 1H in all), 2.14 and 2.17 (both s,
anti- and syn-, 1H in all), 1.85–2.53 (m, 6H in all), 3.24 and 3.40
(both d, syn-, J¼12.5,1H each), 3.61 (s, anti-, 2H), 7.24 and 7.35 (both
d, syn-, J¼8.8, 2H each), 7.23 and 7.37 (both d, anti-, J¼8.8, 2H each).
Elemental analysis calcd (%) for C16H17ClOS: C, 65.63; H, 5.85. Found
(%): C, 65.69; H, 5.76.
Compound 120: 80% from 12, Rf 0.53 (SiO2, ethyl acetate/hexane,
1:10). Elemental analysis calcd (%) for C18H21ClSSi: C, 64.93; H, 6.36.
Found (%): C, 65.30; H, 6.09.
3.3.10. DCHC complex of 2-[1-(4-chlorophenylthio)but-3-yn-2-yl]-
cyclohexanone (15). A 1.0 M solution of the DCHC complex of
vinylacetylene 1a (1.0 ml, 1.0 mmol) was diluted with CH2Cl2 (6 ml)
and cooled to ꢀ70 ꢁC. Then a 1.0 M solution of p-ClC6H4SCl (1.0 ml,
1.0 mmol) in CH2Cl2 was added. After 5 min, a 1.0 M solution of
TiCl4 in CH2Cl2 (1.1 ml, 1.1 mmol) was added with the subsequent
addition, after 5 min, of 1-trimethylsilyloxycyclohexene-1 (5g)
(255 mg, 1.5 mmol). The reaction mixture was kept at ꢀ30 ꢁC for 1
day. Further work-up of the reaction mixture and the isolation of
the target compound were carried out as described in the typical
experimental procedure in the main text. Product 15 was isolated
as a mixture of syn/anti diastereomers (493 mg, 85%, dark brownish
oil, Rf 0.33 (SiO2, ethyl acetate/hexane, 1:10), syn/anti¼12:1, the
ratio was determined by comparison of 1H NMR signal intensity).
Stereochemical assignment was accomplished in the same manner
as for product 13.
3.3.8. DCHC complex of 2-[1-(4-chlorophenylthio)but-3-yn-2-yl]-
cyclopentanone (13). A 1.0 M solution of the DCHC complex of
vinylacetylene 1a (1.0 ml, 1.0 mmol) was diluted with CH2Cl2 (6 ml)
and cooled to ꢀ70 ꢁC. Then a 1.0 M solution of p-ClC6H4SCl (1.0 ml,
1.0 mmol) in CH2Cl2 was added. After 5 min, a 1.47 M ZnCl2/Et2O
catalyst7 (0.10 ml, 0.15 mmol) was added with the subsequent ad-
dition, after 5 min, of 1-trimethylsilyloxycyclopentene-1 (5f)
(234 mg, 1.5 mmol). The reaction mixture was kept at ꢀ30 ꢁC
overnight. Further work-up of the reaction mixture and the
isolation of the target compound were carried out as described
in the typical experimental procedure in the main text. Product
13 was obtained as a mixture of syn/anti isomers (498 mg, 88%,
dark brownish oil, Rf 0.28 (SiO2, ethyl acetate/hexane, 1:10), syn/
anti¼12:1, the ratio was determined by comparison of 1H NMR
signal intensity). Stereochemical assignment was accomplished
using two-dimensional NMR technique and ROESY experiment.
In order to enrich the sample with a minor isomer the latter
was treated with dioxane/HCl complex in CH2Cl2 solution at
ꢀ30 ꢁC. Under these conditions the mixture underwent epi-
merisation to give the ratio of isomers 2:1 with the pre-
dominance of syn-isomer.
Compound 15-syn: 1H NMR (300 MHz, CDCl3): 1.48 (m, 1H), 1.61
(m, 2H), 1.87 (m, 1H), 2.00 (m, 2H), 2.23 (m, 1H), 2.37 (m, 1H), 2.88
(m, 1H), 2.94 (dd, J1¼8.5, J2¼13.4, 1H), 3.31 (dd, J1¼5.5, J2¼13.4, 1H),
3.43 (m, 1H), 5.91 (s, 1H), 7.20 and 7.23 (both d, J¼8.6, 2H each). 13C
NMR (75 MHz, CDCl3): 24.9, 27.3, 29.6, 38.8, 41.3, 42.2, 53.5, 75.1,
96.1, 129.2, 131.2, 132.7, 134.1, 199.5, 210.6.
Compound 15-anti: 1H NMR (300 MHz, CDCl3): 1.63 (m, 3H),
1.92 (m, 1H), 2.00 (m, 2H), 2.28 (m, 1H), 2.40 (m, 1H), 2.71 (m, 1H),
2.88 (m, 1H), 3.24 (dd, J1¼5.5, J2¼12.8, 1H), 3.57 (m, 1H), 6.12 (s, 1H),
7.20 and 7.27 (both d, J¼8.6, 2H each). 13C NMR (75 MHz, CDCl3):
Compound 13 (syn/anti): 1H NMR (300 MHz, CDCl3): 1.81 (m, 2H
in all), 2.10 (m, 2H in all), 2.18 (dd, syn-, J1¼19.0, J2¼8.3,1H), 2.31 (m,
anti-, 2H), 2.40 (dd, syn-, J1¼19.0, J2¼7.5, 1H), 2.49 and 2.84 (both m,